Relevance of ARID1A Mutations in Endometrial Carcinomas

Since the Cancer Genome Atlas (TCGA) project identified four distinct groups based on molecular alterations, mutation analyses have been integrated into the characterization of endometrial carcinomas (ECs). ARID1A seems to be the subunit more involved in the loss of function of the SWI/SNF complex in ECs. The aim of this study is to define the relevance of ARID1A alterations in a cohort of EC, studying the possible associations between DNA mutation (genomic level), RNA expression (transcriptomic level), and protein expression (proteomic level). A total of 50 endometrial carcinomas were characterized for ARID1A mutations (using targeted DNA next-generation sequencing—NGS), ARID1A gene expression (using RNAseq and qRT-PCR), and ARID1A protein expression (using immunohistochemistry—IHC). Moreover, we have investigated if ARID1A mutations may alter the protein structure, using the Protein Data Bank sequence. We found a good correlation between ARID1A mutations and protein immunostaining, even if we did not find statistically significant differences in the ARID1A expression levels. In conclusion, our data demonstrated that the molecular characterization of ARID1A should be associated with IHC analysis, mainly in those cases harboring “novel” ARID1A mutations or in those alterations with “uncertain” pathogenic significance.

[1]  P. Hrelia,et al.  Identification of miR-499a-5p as a Potential Novel Biomarker for Risk Stratification in Endometrial Cancer , 2021, Frontiers in Oncology.

[2]  P. Hrelia,et al.  Can miRNAs be useful biomarkers in improving prognostic stratification in endometrial cancer patients? An update review , 2021, International journal of cancer.

[3]  Shouying Xu,et al.  The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression? , 2021, Frontiers in Oncology.

[4]  Yina Gao,et al.  Downregulated ARID1A by miR-185 Is Associated With Poor Prognosis and Adverse Outcomes in Colon Adenocarcinoma , 2021, Frontiers in Oncology.

[5]  A. Brandes,et al.  Molecular alterations in pancreatic tumors , 2021, World journal of gastroenterology.

[6]  G. Troncone,et al.  Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations , 2021, Journal of Clinical Pathology.

[7]  D. Santini,et al.  What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors , 2021, Diagnostics.

[8]  D. Bowtell,et al.  Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma , 2021, Cancers.

[9]  D. Santini,et al.  ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification , 2021, Cancers.

[10]  S. Piana,et al.  Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature , 2021, Diagnostics.

[11]  F. Dimaio,et al.  A Structural Model of the Endogenous Human BAF Complex Informs Disease Mechanisms , 2020, Cell.

[12]  A. Giordano,et al.  An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach , 2020, International journal of molecular sciences.

[13]  G. Tallini,et al.  Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel , 2020, Diagnostics.

[14]  V. Balis,et al.  Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes (Review) , 2020 .

[15]  Peter B. McGarvey,et al.  Proteogenomic Characterization of Endometrial Carcinoma , 2020, Cell.

[16]  Yanhui Xu,et al.  Structure of nucleosome-bound human BAF complex , 2020, Science.

[17]  A. Gavin,et al.  Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. , 2018, European journal of cancer.

[18]  Radhika Mathur ARID1A loss in cancer: Towards a mechanistic understanding , 2018, Pharmacology & therapeutics.

[19]  S. Miyamoto,et al.  Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration , 2018, Scientific Reports.

[20]  Helen M Berman,et al.  Development of a Prototype System for Archiving Integrative/Hybrid Structure Models of Biological Macromolecules. , 2018, Structure.

[21]  R. Bernards,et al.  ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors , 2018, Oncogene.

[22]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[23]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[24]  K. Wong,et al.  Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells , 2016, Oncotarget.

[25]  H. Putter,et al.  Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts , 2016, Clinical Cancer Research.

[26]  D. Aoki,et al.  ARID1A gene mutation in ovarian and endometrial cancers (Review) , 2015, Oncology reports.

[27]  L. Wood,et al.  Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis , 2015, Oncotarget.

[28]  Wei Zhang,et al.  ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. , 2015, Cancer discovery.

[29]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[30]  Steven L Salzberg,et al.  HISAT: a fast spliced aligner with low memory requirements , 2015, Nature Methods.

[31]  S. Salzberg,et al.  StringTie enables improved reconstruction of a transcriptome from RNA-seq reads , 2015, Nature Biotechnology.

[32]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[33]  P. Goodfellow,et al.  Evaluation of incidence and prognostic significance of newly identified hotspot mutations in DNA polymerase epsilon (POLE) in endometrial cancer: Contextualizing findings from The Cancer Genome Atlas Research Network , 2014 .

[34]  H. Morreau,et al.  Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer , 2013, Modern Pathology.

[35]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[36]  M. Takano,et al.  Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin , 2013, The journal of obstetrics and gynaecology research.

[37]  S. Wiseman,et al.  Loss of BAF250a (ARID1A) is frequent in high‐grade endometrial carcinomas , 2011, The Journal of pathology.

[38]  I. Shih,et al.  Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma , 2011, The American journal of surgical pathology.

[39]  T. Goto,et al.  Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases , 2011, International Journal of Clinical Oncology.

[40]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[41]  N. Isern,et al.  Structure and DNA-binding Sites of the SWI1 AT-rich Interaction Domain (ARID) Suggest Determinants for Sequence-specific DNA Recognition* , 2004, Journal of Biological Chemistry.

[42]  A. Perrone,et al.  Endometrial carcinoma: past, present, and future , 2021 .

[43]  H. Katagiri,et al.  Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. , 2013, Human pathology.